At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Dutasteride +1 moredrug
Likely dose
Dutasteride 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Dutasteride and Placebo for Prostate Cancer. Completed, enrolled 20 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsUniversity of Chicago, Northwestern University
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2008
Primary CompletionMay 2013
TodayJul 2026
First PostedApr 29, 2008
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 18.2 years ago
Interventions
Dutasteridedrug
0.5 mg capsule given orally on daily basis
Placebodrug
Identical placebo